Portugal's quarter-century experiment with drug decriminalization offers a blueprint for U.S. policymakers grappling with an overdose crisis that killed 70,000 Americans in 2025, according to a new analysis by University of Maine researchers.
The decline from nearly 108,000 deaths the previous year marks progress, but the toll remains staggering. Portugal's approach—treating drug use as a public health issue rather than a criminal one—has produced measurably different outcomes over the same timeframe.
"Reducing the harms of drug use requires painstakingly building and sustaining a system that connects people with treatment, healthcare and social support," wrote Karyn Sporer and Robert Glover in their analysis published via The Conversation.
Portugal decriminalized possession of all drugs in 2001, shifting resources from incarceration to treatment infrastructure. The country now refers people caught with small amounts to "dissuasion commissions" staffed by social workers, legal experts and healthcare providers rather than judges.
The Infrastructure Question
The Portuguese model works because the country invested heavily in the unsexy parts of public health: clinics, counselors, housing assistance and job training. It's not just decriminalization—it's what comes after.
Several U.S. states have moved toward cannabis legalization and some cities have experimented with decriminalizing other substances. But few have matched Portugal's commitment to the treatment and support infrastructure that makes decriminalization work. Oregon's Measure 110, which decriminalized small amounts of drugs in 2020, has faced criticism partly because the promised treatment network lagged behind the policy change.
The cannabis industry has long argued that legalization paired with regulation and public health measures beats prohibition. Portugal's data appears to support that framework—when applied consistently and funded adequately.
What the Numbers Show
Portugal's drug-related deaths remain among the lowest in Europe, at roughly 6 per million residents. The U.S. rate exceeds 200 per million. HIV infections among people who inject drugs dropped dramatically in Portugal after decriminalization, while overdose deaths fell and remained low.
The researchers note that Portugal's success didn't happen overnight. It took years of sustained investment and political will to build treatment capacity that could absorb demand. The country also maintained decriminalization through multiple changes in government—something U.S. states have struggled to do with cannabis policy, let alone broader drug reform.
Implications for Cannabis Policy
For the cannabis industry, Portugal's experience validates arguments that legalization works best when paired with robust regulatory frameworks and public health resources. The country treats cannabis like other drugs under its decriminalization scheme, though it remains illegal to sell.
Several U.S. advocates have pointed to Portugal when arguing for broader drug policy reform, including groups pushing for federal cannabis rescheduling and state-level psychedelic legalization. The model suggests that removing criminal penalties is only half the equation—the other half is ensuring people have access to healthcare, treatment and social services.
As more states consider cannabis legalization and some explore decriminalizing psychedelics, Portugal's 25-year track record offers a clear message: policy change without infrastructure investment produces mixed results at best.
The researchers emphasize that Portugal's approach required consistent funding, political commitment across administrations, and a fundamental shift in how society views drug use. Whether American states have the appetite for that level of sustained investment remains an open question.
This article is based on original reporting by www.marijuanamoment.net.
